Alteogen completes clinical trial of ‘Herceptin’ biosimilar

Alteogen announced the Phase 1 clinical trial of a biosimilar of Herceptin, a breast cancer therapy, which has been conducted in Canada since February, was successfully completed.

Alteogen has carried out the Phase 1 clinical trial after the company acquired its approval from ‘Health Canada’ last February. The clinical trial was conducted to prove equivalence and safety of the Herceptin biosim...